Desentum
  • Home
  • Technology
  • Company
  • News
  • Contact
  • Suomi
Select Page

Desentum reports strong safety and immunological data from Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX

by kati.sallinen@desentum.fi | Apr 2, 2025 | News

Desentum Oy, a clinical-stage biopharmaceutical company developing novel immuno­therapies for treating allergies, announces positive clinical data with birch pollen allergy vaccine DM-101PX. The short-course treatment was found to be safe and well tolerated in birch...

Pekka Mattila conferred as Honorary Doctor at the University of Eastern Finland

by kati.sallinen@desentum.fi | Jun 10, 2024 | News

Pekka Mattila, CEO of Desentum was conferred as Honorary Doctor at the University of Eastern Finland on Jun 7, 2024. The Faculty of Science, Forestry and Technology stated the following: “In 2011, Pekka Mattila and researchers from the Department of Chemistry at the...
Next Entries »

Viimeisimmät artikkelit

  • Desentum’s UPSIT study with birch pollen allergy treatment DM-101PX approved by Paul-Ehrlich-Institut in Germany
  • Desentum raises €28 million to develop safer, more effective allergen immunotherapy
  • New peer-reviewed publication on Desentum’s investigational birch pollen allergen immunotherapy DM-101PX
  • Desentum to present at the 2026 EAACI annual congress in Istanbul this week
  • Desentum’s 18 M€ share issue from private investors and family offices breaks a record for unlisted growth companies in Finland

Viimeisimmät kommentit

No comments to show.

DESENTUM OY

Tekniikantie 14, 02150 Espoo, Finland
info@desentum.fi

  • Follow
  • Follow

© Desentum Oy

Privacy policy
​​Cookie settings
Website: Räikee Oy

© Desentum Oy

Tietosuojaseloste
​​Evästeasetukset
Nettisivut: Räikee Oy